Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
Date:10/4/2010

SAN DIEGO, Oct. 4 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the 28th Annual Scientific Meeting of The Obesity Society. This meeting will be held at the San Diego Convention Center, October 8-12, 2010.Sunday, October 10:  Embargo Lifts October 10 at 12:30 p.m. PTPoster Presentation
Abstract: 478-P
Presenter: Louis Aronne, M.D., New York Weill Cornell-Columbia Presbyterian Hospital, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Markers of Cardiometabolic Risk: A Pooled Analysis of Two Phase 3, 56-Week, Double-Blind, Placebo-Controlled Studies"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 480-P
Presenter: Ken Fujioka, M.D., Scripps Clinic, La Jolla, CA
Title: "Naltrexone SR/Bupropion SR Combination Therapy Improves Control of Eating and Reduces Food Cravings in Overweight/Obese Subjects"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 482-P
Presenter: F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital and Columbia University, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Had No Effect on Depression or Suicidal Ideation: A Pooled Analysis From the Contrave Obesity Research Program"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 479-P
Presenter: Raymond A. Plodkowski, M.D., University of Nevada School of Medicine, Reno, NV
Title: "COR I: Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Weight-Related Quality of Life in a Phase 3, 56-Week, Double-Blind, Placebo-Cont
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
2. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
3. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
4. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
5. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
6. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
7. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
8. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
11. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Groton , Connecticut MORRISVILLE, N.C., May ... of APIs, intermediates and Drug Products to the pharmaceutical industry, ... announce the recent award by Pfizer Inc. as the 2008 ... Groton, Connecticut R&D center on May 1, 2009. The award ...
... Blinatumomab in NHL and ALL Highlighted at the ... Combination Data in Breast Cancer to Be Presented ... MeetingBETHESDA, Md., May 20 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ...
... WOODMERE, N.Y., May 19 In an eleventh-hour attempt ... QGLY ) has issued a press release claiming that ... a key staff member of a subsidiary of Quigley, and ... who have offered their own slate of Quigley,s Board of ...
Cached Biology Technology:Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
... Synergistic enzyme mix (Thermoprime Plus DNA ... At least four times higher fidelity than ... of standard Taq DNA polymerase, Amplifies DNA ... PCR, long PCR, PCR for cloning and ...
... Assay Kit (E-22013) provides,researchers with a ... lysozyme,activity in solution. This fluorescence-based assay ... U/mL (Figure 1). The assay,measures lysozyme ... are labeled to such a degree ...
... An immuncapture enzyme-activity assay based on ... captured on monoclonal antibody coated microtiter plate. ... standards, samples or controls, 2nd ... The assay is intended for the determination ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. iEMS Incubator/Shaker ... one-cabinet model, allowing the capacity ...
Biology Products: